Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2007; 13(8): 1162-1169
Published online Feb 28, 2007. doi: 10.3748/wjg.v13.i8.1162
Published online Feb 28, 2007. doi: 10.3748/wjg.v13.i8.1162
Figure 1 Inhibition of growth of human gastric cancer xenografts in an athymic mouce model.
A: tumor tissues treated with EGCG or PBS on d 28 after treatment; B: an average of 60.4% suppression of primary tumor growth in the EGCG treatment group compared with control group; C: tumor growth suppression curve: volumes of EGCG treatment group versus PBS treatment group on indicated days. Data are presented as mean ± SE (n = 6, aP < 0.05, bP < 0.01).
- Citation: Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 2007; 13(8): 1162-1169
- URL: https://www.wjgnet.com/1007-9327/full/v13/i8/1162.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i8.1162